German Breast News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from German breast. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In German Breast Today - Breaking & Trending Today

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Forschungs Gmb , Kendra Sweeney , Brigitte Hanke , Company Annual Report On Form , German Breast Group , Company Pharma Services Division , Neogenomics Inc , Annual Meeting , Neogenomic Radar , Professor Sibylle Loibl , Chief Executive Officer , German Breast , Breakthrough Device Designation , Pharma Services Division , Privacy Practices , Annual Report , Investor Relations ,

BrighTNess Follow-Up Data Shed Light on TNBC Therapy

BrighTNess Follow-Up Data Shed Light on TNBC Therapy
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Monica Arnedos , Institut Bergoni , German Breast Group , European Society For Medical Oncology , Sibylle Loibl , German Breast , European Society , Medical Oncology , Study Details , Lancet Oncology , ஜெர்மன் மார்பக குழு , ஐரோப்பிய சமூகம் க்கு மருத்துவ புற்றுநோயியல் , ஜெர்மன் மார்பக , ஐரோப்பிய சமூகம் , மருத்துவ புற்றுநோயியல் , படிப்பு விவரங்கள் ,

Adjuvant Palbociclib Fails in Early, High-Risk Breast Cancer

email article
Adding a year of CDK4/6 inhibition to adjuvant endocrine therapy failed to improve invasive disease-free survival (iDFS) in early hormone receptor (HR)-positive breast cancer patients who had residual disease following neoadjuvant chemotherapy, a phase III trial showed.
In the PENELOPE-B study of over 1,200 patients, no difference in the primary endpoint of iDFS was observed between the group receiving palbociclib (Ibrance) and those assigned to placebo, after a median follow-up of 43 months (stratified HR 0.93, 95% CI 0.74-1.17,
P=0.525), reported Sibylle Loibl, MD, PhD, of the German Breast Group.
The addition of 1 year of palbociclib to endocrine therapy in patients with hormone receptor-positive/HER2-negative breast cancer and at high risk of relapse after neoadjuvant chemotherapy does not improve invasive disease-free survival, she said during her presentation at the virtual San Antonio Breast Cancer Symposium (SABCS). No group could be ....

San Antonio , United States , Ruth Oregan , Ian Ingram , University Of Wisconsin , German Breast Group , Sibylle Loibl , German Breast , San Antonio Breast Cancer Symposium , Rutho Regan , Medpage Today , Deputy Managing Editor , Antonio Breast Cancer , சான் அன்டோனியோ , ஒன்றுபட்டது மாநிலங்களில் , ரூத் ஒரேகன் , ஈயந் இஂக்ரம் , பல்கலைக்கழகம் ஆஃப் விஸ்கான்சின் , ஜெர்மன் மார்பக குழு , ஜெர்மன் மார்பக , சான் அன்டோனியோ மார்பக புற்றுநோய் சிம்போசியம் , துணை நிர்வகித்தல் ஆசிரியர் , அன்டோனியோ மார்பக புற்றுநோய் ,